Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Two new biosimilars 'could save NHS millions'

Two biosimilar medicines for the treatment of patients with specific blood cancers and a range of inflammatory conditions have been made available for patients in the UK.

Sandoz UK, a division of Swiss global healthcare company Novartis, announced that Rixathon, a version of rituximab, for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia and immunological diseases such as rheumatoid arthritis, and Erelzi, a biosimilar of etanercept, for patients with inflammatory conditions including rheumatoid arthritis and plaque psoriasis, could provide much-needed cost savings for the NHS.

In line with recommendations from NHS England, both drugs will be made available on the NHS with no requirement for a separate appraisal.

Tim de Gavre, country head for Sandoz UK, the generics arm of Swiss global healthcare company Novartis, said the availability of Rixathon and Erelzi marked “an important milestone for the NHS and for patients”.

He said: “The availability of new biosimilar medicines — which offer equal efficacy to the originator products and provide both patients and physicians more choice in treatment options — offer a real opportunity for cost savings within the NHS, which may then be reinvested back into the health service.

“This comes at a crucial time for the NHS, which is currently constrained by enormous financial pressure. The hope is that rapid uptake of the medicines will translate to cost savings for the NHS which patients may quickly benefit from.”

Approval and the subsequent availability of these medicines was based on analytical, pre-clinical and clinical data demonstrating biosimilarity to the respective reference medicines.

In 2015–2016, the NHS spent more than £415 million on rituximab and etanercept[1].

Sandoz said it is looking to undercut current listed market pricing for both drugs by 8–10%. Further discounts may be negotiated locally by the NHS.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203157

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Foundation in Pharmacy Practice

    Foundation in Pharmacy Practice

    A practical and succinct overview of the principal pharmacy practice topics, for new pharmacy students.

    £33.00Buy now
  • Non-medical Prescribing

    Non-medical Prescribing

    An essential new guide designed to ensure confident prescribing in specialist areas.

    £27.00Buy now
  • Dale and Appelbe's Pharmacy and Medicines Law

    Dale and Appelbe's Pharmacy and Medicines Law

    This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.

    £57.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Novartis

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.